贝伐珠单抗相关性肠穿孔病例报道与文献综述-临床药物治疗.PDF

临床药物治疗杂志2014 年12月第12卷增刊Clinical Medication Journal,Dec 2014,Vol 12,Supple ·药物与临床· . . 贝伐珠单抗相关性肠穿孔：病例报道与文献综述 1 2 1* 张萌萌 陈森 翟所迪 1　北京大学第三医院药剂科（北京 100191 ） 2 北京大学第三医院肿瘤化疗与放射病科（北京 100191 ） 【摘要】目的：探讨贝伐珠单抗相关性肠穿孔的发生率、临床表现、发生机制、危险因素和管理， 为临床安全用药提供参考。方法：报道1 例使用化疗联合贝伐珠单抗治疗442 天后发生肠穿孔的Ⅳ 期结肠癌病例，并回顾相关研究文献。结果与结论：贝伐珠单抗相关性肠穿孔的发生率低，患者可 出现腹痛、恶心呕吐、发热等症状，其发生机制尚不明确，多种危险因素可使其发生风险增加，临 床中应注意对高危患者的识别和管理。 【关键词】贝伐珠单抗；肠穿孔；严重不良事件 【中图分类号】R978.7 ；R512.62 【文献标志码】A doi:10.3969/j.issn.1672-3384.2014.013 Bevacizumab-associated Bowel Perforation: a Case Report and Literature Review 1 2 1* ZHANG Meng-meng , CHEN Sen , ZHAI Suo-di . 1 Department of Pharmacy, Peking University Third Hospital, Beiing 100191, China. 2 Department of Tumor Chemotherapy and Radiation Sickness, Peking University Third Hospital, Beiing 100191, China. Abstract Objective: To investigate the incidence, clinical manifestations, mechanism, risk factors 【 】 and management of bevacizumab-associated bowel perforations. Methods: A stage IV colon cancer patient with bevacizumab-associated bowel perforation 442 days after the initiation of chemotherapy and bevacizumab was reported. And relevant research literatures were reviewed. Results and Conclulion : The incidence of bevacizumab-associated bowel perforations is low. Abdominal pain, nausea and vomiting, and fever could be complained by the patients. Although the mechanism is unknown now, many risk factors would contribute to the occurrence of this kind of severe adverse events. The detection and management of these patients should be emphasized. Keywords bevacizumab; bowel perforations; severe adverse events 【 】 贝伐珠单抗是一种重组人源化单克隆抗体， 脑胶质细胞瘤、转